The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.
 
Andrew E. Sloan
Stock and Other Ownership Interests - Surgical Management Professionals
Consulting or Advisory Role - Monteris Medical
Patents, Royalties, Other Intellectual Property - Radiosurgical Planning
 
Mark R. Gilbert
Honoraria - Abbvie; Cell Medica; Genentech/Roche; HERON; Merck; Wellcome Trust
 
Peixin Zhang
No Relationships to Disclose
 
Kenneth D. Aldape
Consulting or Advisory Role - Celldex
Speakers' Bureau - Merck
Travel, Accommodations, Expenses - Merck
 
Jing Wu
No Relationships to Disclose
 
Lisa R. Rogers
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - AbbVie; Agios; AstraZeneca; Aurora Biopharma; Genentech/Roche; GW Pharmaceuticals; Immunomic Therapeutics; Kadmon; Karyopharm Therapeutics; Lilly; Monteris Medical; Vascular Biogenics; Vivus; ZIOPHARM Oncology
Speakers' Bureau - Merck
Research Funding - Abbvie (Inst); Agios (Inst); Angiochem (Inst); ARIAD (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); ImmunoCellular Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly; Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Sanofi (Inst); Vascular Biogenics (Inst)
 
Igor J. Barani
No Relationships to Disclose
 
Fabio Massaiti Iwamoto
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Merck; Novocure; Regeneron
Speakers' Bureau - Prime Oncology
 
Raju R. Raval
No Relationships to Disclose
 
Alfredo Daniel Voloschin
No Relationships to Disclose
 
John Frederick De Groot
Employment - Helsinn Therapeutics (I); ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; AstraZeneca; Boston Biomedical; CarThera; Celldex; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Merck; Novogen; Omniox; Oxigene; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
 
Minhee Won
No Relationships to Disclose
 
Minesh P. Mehta
Leadership - Oncoceutics
Stock and Other Ownership Interests - Pharmacyclics
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Celgene; IBA; Insys Therapeutics; Oncoceutics; Remedy Pharmaceuticals; Tocagen; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
Other Relationship - Monteris Medical